The paper is titled 'Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer's already receiving donepezil: a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial', and contains an analysis of the overall data from the Phase II clinical trial for Alzheimer's disease conducted in
The phase II clinical trial was conducted at twelve domestic institutions to evaluate the safety and efficacy of GV1001, and confirmed statistically significant improvements in both the primary and secondary endpoints, the Severe Impairment Battery (SIB) (7.1 points) and the neuropsychiatric inventory (NPI) score, respectively. In particular, GV1001 was well tolerated without any clinically significant side effects or adverse drug events.
Professor
A GemVax official said: "The publication of GV1001 phase II Alzheimer's disease clinical trial results in the highly prestigious journal 'Alzheimer's Research & Therapy' is an undisputable success and scientifically meaningful achievement. We will continue to strive in the upcoming clinical trials domestically and abroad to develop what we hope be a truly breakthrough treatment of Alzheimer's disease."
Meanwhile, GemVax recently submitted GV1001's Phase III clinical trial Investigational New Drug (IND) application for Alzheimer's disease to the
'Alzheimer's Research & Therapy' is one of the world's top 10% of most prominent international journals in the field of Alzheimer's disease.
Link: https://link.springer.com/article/10.1186/s13195-021-00803-w#citeas
Contact:
+44 7711 821527
richard@rhapr.eu
View original content:http://www.prnewswire.com/news-releases/gemvaxs-highly-promising-phase-ii-alzheimers-disease-clinical-trial-results-targeting-telomerase-published-in-prestigious-alzheimers-research--therapy-journal-301258354.html
SOURCE GemVax
© Canada Newswire, source